The Problem:
Anxiety disorders affect 301M people a year - yet remain the most undertreated.
Every year they cost the global economy over US$1 trillion, projected to reach US$16 trillion by 2030.
Despite proven treatments like Exposure Therapy, 72.1% of people can’t access care due to cost, stigma, or clinician shortages.
Why It Matters For Health Plans
Anxiety and related disorders drive:
27% more ER visits and
2.5× higher utilization
$1,657 higher annual costs
per member
Over $82 billion in total mental health costs each year in the U.S.
The Solution
Clinically Validated Virtual Reality Exposure Therapy
oVRcome delivers Exposure Therapy via a smartphone and headset, combining decades of clinical evidence with the reach and affordability of digital care.
oVRcome drives better outcomes at lower cost.
60.7%
shorter treatment duration
5%
of traditional
therapy cost
86.5%
client
adherence
32.1%
faster return to work
& daily life
34.1%
lower benefit cost (~$29K → ~$19K USD)
Evidence-Based Results
Clinical outcomes that speak volumes
Across oVRcome’s clinical trials and pilot programs:
75% reduction
in phobia symptoms
Large effect size
(Cohen’s d = 1.3)
Phobia Trial
50%
reduction
in social anxiety symptoms
43% improvement
General Anxiety
(DASS-21)
83% reduction
in vaping addiction
(15-18 year olds)
55% improvement
AFQ
31% improvement
PTSD (PCL-5)
19% improvement
Depression (DASS-21)
"I am an oVRcome cheerleader. Love it so far as do my clients. I am a big fan of the platform and am introducing it to many of my colleagues who are equally excited."
Clinician for Fear of Driving and GAD
Reimbursement Pathways
oVRcome integrates seamlessly into existing care and billing workflows.
Clinician-billed:
reimbursable under existing psychotherapy codes (90832–90837) and Remote Therapeutic Monitoring codes (98975–98978).
Plan-directed pilots:
custom PMPM or outcomes-based contracts to validate cost savings and member outcomes.
Founder Story
A personal mission to transform mental health
Founder Adam Hutchinson created oVRcome after overcoming his own severe social anxiety through exposure therapy. After selling his previous startup to THL, he built oVRcome to make effective therapy available to everyone, anywhere.
Request a Demo to learn how we can help your members
You can also share your address and phone number to receive a free smartphone VR headset! (US only)
Community
Support
Company
Get the App
Copyright © 2025 oVRcome. All rights reserved.
Source:
1. Alonso, J., Liu, Z., Evans-Lacko, S., Sadikova, E., Sampson, N., Chatterji, S., … Kessler, R. C. (2018). Treatment gap for anxiety disorders is global: Results of the World Mental Health Surveys in 21 countries. Depression and Anxiety, 35(3), 195–208. https://doi.org/10.1002/da.22711 2. The Lancet Global Health. (2020). Mental health matters. The Lancet Global Health, 8(11), e1352. https://doi.org/10.1016/S2214-109X(20)30432-0
Soni, A. (2019). Health care expenditures for treatment of mental disorders: Estimates for adults ages 18 and older, U.S. civilian noninstitutionalized population, 2016 (Statistical Brief No. 539). Agency for Healthcare Research and Quality, U.S. Department of Health & Human Services. https://meps.ahrq.gov/data_files/publications/st539/stat539.pdf
Panchal, S. K. (2017). Cost of illness study of anxiety disorders for the ambulatory adult population of the U.S. [Doctoral dissertation, University of Tennessee Health Science Center]. University of Tennessee Health Science Center Digital Commons. https://dc.uthsc.edu/dissertations/370
Iturralde, E., Chi, F. W., Grant, R. W., Weisner, C., Van Dyke, L., Pruzansky, A., Bui, S., Madvig, P., Pearl, R., & Sterling, S. A. (2019). Association of anxiety with high-cost health care use among individuals with type 2 diabetes. Diabetes Care, 42(9), 1669-1674. https://doi.org/10.2337/dc18-1553